Market Research Report
Global Gene Therapy Market - 2019-2026
|Published by||DataM Intelligence||Product code||879324|
Delivery time: 1-2 business days
|Global Gene Therapy Market - 2019-2026|
|Published: January 1, 2020||Content info:||
Global Gene Therapy Market Overview
The global gene therapy market size was worth $ XX billion in2018 and is forecasted to reach $ XX billion by 2026, at a CAGR of XX% during the forecast period.
Gene therapy is introduction of DNA into a patient to treat a genetic disease. The new DNA usually contains a functioning gene to correct the effects of a disease-causing mutation.
Gene therapy uses sections of DNA to treat or prevent disease. The DNA is carefully selected to correct the effect of a mutated gene that is causing disease. The technique was first developed in 1972 but has, so far, had limited success in treating human diseases.
Researchers are studying gene therapy for a number of diseases such as severe combined immune deficiencies, hemophilia, Parkinson's disease, cancer and even HIV through a number of approaches.
Global Gene Therapy Market -Market Dynamics
Advancements in treatments to cure diseases such as cancer, neuro and cardio diseases is driving the global gene therapy market in recent years and anticipated to remain same over the forecast period. For instance, in 2017, in France, researchers from Bluebird Bio announced that a teenage boy in France had been cured of sickle-cell disease after receiving an experimental gene therapy. Scientists removed stem cells from the boy's bone marrow and modified them in the lab by introducing copies of a gene to prevent his red blood cells from becoming sickled.
Increasing number of chronic disease such as cancer, asthma, diabetes and COPD are boosting the requirement of gene therapy over the forecast period. According to National Cancer Institute in 2018, in United States, an estimated 1,735,350 new cases of cancer will be diagnosed and 609,640 people will die from the disease.
Technological advancements, increasing clinical therapy researches are boosting the global gene therapy market in recent years.
However, high cost of gene therapies are hampering the global gene therapy market over the forecast period.
Global Gene Therapy Market - Segment Analysis
Based on application, global gene therapy market is segmented into oncology, neurological diseases, inherited diseases, cardiac diseases and infectious diseases. Oncology had the highest market share in 2018 and expected to remain dominant same over the forecast period. Cancers for which gene therapy products are being developed include glioblastoma, metastatic melanoma, head and neck cancer, prostate cancer, renal cell cancer and colorectal cancer. For instance in 2017, FDA approved gene therapy treatment for cancer known as CAR-T therapy. The therapy is designed to treat an often-lethal type of blood and bone marrow cancer that affects children and young adults and will be sold by Novartis for $475,000.
Gene therapy applications in cardio diseases have the second largest share in recent years due to increasing number of heart related diseases. According to World Health Organization in 2017, 17.9 million people died from CVDs in 2016 globally, representing 31% of all global deaths. Researchers and scientists are has been working effectively on gene therapy in cardiology areas to provide solutions.
Based on vector type global gene therapy market is categorized into viral vectors and non-viral vectors. Viral vector had the dominant share in recent years and anticipated to remain same over the forecast period. In gene therapy, viral vectors can be used for delivery of functional genes to replace defective genes to cure genetic disorders. Viral vectors are preferred more as they provide high efficiency gene transduction, specific delivery of genes to target cells, improved efficacy and safety and reduced administration dose. The major viral vectors are retrovirus, lentivirus, vaccinia virus, adenovirus, adeno-associated virus, cytomegalovirus, sendai virus and others.
Based on gene type, global gene therapy is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors and others.
Global Gene Therapy Market - Geographical Analysis
The global gene therapy market is segmented into North America, Europe, Asia Pacific, South America and rest of the world.
North America is dominating the global gene therapy market due to rapid advancements in gene therapy market. For instance, in 2018, Spark Therapeutics developed Luxturna that was approved by the Food and Drug Administration (FDA) for treatment of RPE65-mediated inherited retinal dystrophy. Luxturna is the first targeted gene therapy approved in the US, representing a huge milestone in medical care.
Europe has the second largest market share in global gene therapy market due to increasing number of chronic diseases such as cancer and heart attack. According to WHO, with more than 3.7 million new cases and 1.9 million deaths each year, cancer represents the second most important cause of death and morbidity in Europe.
The Asia pacific Gene Therapy market is anticipated to grow at the fastest CAGR during the forecast period due to the presence of developed and developing countries such as China, India and Japan.
Global Gene Therapy Market - Competitive Analysis
Key pharmaceutical companies are investing significant money in the clinical research and development of gene therapy products. Competition is immense in global gene therapy market and companies see a huge opportunity in gene therapy market.
The key players in gene therapy market are Novartis AG, UniQure N.V, Spark Therapeutics LLC, Bluebird Bio, Kite Pharmaceuticals, Gilead Sciences, Inc, Human Stem Cell Institute, Shire Plc, Cellectis and GlaxoSmithKline plc.
Swiss drugmaker Novartis has received US approval for its spinal muscular atrophy gene therapy Zolgensma pricing the one-time treatment at a record $2.125m.
On February 15, 2019, Gene therapy pioneer James Wilson launches startup Passage Bio with $115.5 million. It has raised $115.5 million in series financing to develop gene therapies for rare genetic diseases of the central nervous system.
In 2019, Novartis has a deal with Spark to market Luxturna in Europe, and is therefore at the forefront of not only the groundbreaking R&D behind cell and gene therapy, but is also looking to lead the revolution in pricing and reimbursement required to make them a commercial success